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Abstract
Background: Studies have shown that the Mycobacterium tuberculosis Beijing genotype is an emerging pathogen that is
frequently associated with drug resistance. This suggests that drug resistant Beijing strains have a relatively high
transmission fitness compared to other drug-resistant strains.
Methods and Findings: We studied the relative transmission fitness of the Beijing genotype in relation to anti-tuberculosis
drug resistance in a population-based study of smear-positive tuberculosis patients prospectively recruited and studied
over a 4-year period in rural Vietnam. Transmission fitness was analyzed by clustering of cases on basis of three DNA typing
methods. Of 2531 included patients, 2207 (87%) were eligible for analysis of whom 936 (42%) were in a DNA fingerprint
cluster. The clustering rate varied by genotype with 292/786 (37%) for the Beijing genotype, 527/802 (67%) for the East-
African Indian (EAI) genotype, and 117/619 (19%) for other genotypes. Clustering was associated with the EAI compared to
the Beijing genotype (adjusted odds ratio (ORadj) 3.4: 95% CI 2.8–4.4). Patients infected with streptomycin-resistant strains
were less frequently clustered than patients infected with streptomycin-susceptible strains when these were of the EAI
genotype (ORadj 0.6, 95% CI 0.4–0.9), while this pattern was reversed for strains of the Beijing genotype (ORadj 1.3, 95% CI
1.0–1.8, p for difference 0.002). The strong association between Beijing and MDR-TB (ORadj 7.2; 95% CI 4.2–12.3) existed only
if streptomycin resistance was present.
Conclusions: Beijing genotype strains showed less overall transmissibility than EAI strains, but when comparisons were
made within genotypes, Beijing strains showed increased transmission fitness when streptomycin-resistant, while the
reverse was observed for EAI strains. The association between MDR-TB and Beijing genotype in this population was strongly
dependent on resistance to streptomycin. Streptomycin resistance may provide Beijing strains with a fitness advantage over
other genotypes and predispose to multidrug resistance in patients infected with Beijing strains.
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Introduction
Twenty years after the introduction of WHO’s DOTS strategy,
tuberculosis (TB) remains a common and often deadly infectious
disease. In 2010, there were an estimated 9.4 million incident cases
of TB with more than 1.8 million deaths around the world [1].
Resistance of Mycobacterium tuberculosis to anti-tuberculosis drugs is
one of the major challenges to TB control, particularly multi-drug
resistance (MDR), defined as resistance to at least isoniazid and
rifampicin, the two most powerful first-line anti-TB drugs [2].
MDR-TB is associated with high rates of failure and death when
treated with the standard first-line treatment regimens, as is
common in most high-burden countries [3]. In 2008, the WHO
estimated 3.6% of all incident TB cases globally to have MDR-
TB, with the proportion of MDR-TB ranging from 0% to 28%
among new, and from 0% to 61.6% among previously treated TB
patients [3].
Although resistance to TB drugs is considered a man-made
amplification of a natural phenomenon due to inadequate
treatment regimens and incomplete treatment adherence [4],
recent studies have suggested an additional role of the causative
bacteria, in particular for M. tuberculosis Beijing genotype strains.
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First described in 1995, the Beijing genotype probably originates
from East Asia but has been encountered in many countries
worldwide, notably the former Soviet Union where major
problems with anti-TB drug resistance exist [5,6]. This genotype
has also been associated with drug resistance in other areas [5,7,8].
In studies from Europe, South Africa, Taiwan and Malawi, Beijing
strains were predominant among young age groups, suggesting
recent spread and emergence [8,9,10,11,12,13], while data from
the Gambia indicated that Beijing strains may have shorter
incubation periods than other genotypes [14]. Molecular analyses
suggest that this genotype has higher frequencies of particular drug
resistance-conferring mutations, possibly due to alterations in
genes that prevent mutation in genes encoding for drug resistance
[15,16,17,18]. This may imply that Beijing strains have an
increased transmission fitness compared to other genotypes of M.
tuberculosis that predominate in these settings. This increased fitness
could play a role for all forms of resistance in general or especially
for strains that display (multi)drug-resistance. Such increased
fitness would be reflected in e.g. increased transmissibility and thus
increased rates of DNA fingerprint clustering
[8,9,10,11,12,13,14,15] though several studies assessed fingerprint
clustering of drug-resistant strains or strains of specific genotypes,
few have looked at both in a population-based design.
Vietnam is one of 22 high burden countries in the world [1].
The prevalence of MDR-TB among new TB patients is around
2.4%, but considerably higher in previously treated cases [1,3].
Previous studies have shown that the prevalence of M. tuberculosis
Beijing genotype in Vietnam was 53% in urban and 35% in rural
areas [19,20]. This genotype was found to be more frequent in
young patients, strongly associated with MDR-TB, and possibly
associated with relapse [21,22]. We therefore hypothesized that
the Beijing genotype has increased transmission potential when
(multi-)drug-resistant in comparison to other strains circulating in
Vietnam.
In order to test this hypothesis, we assessed the relative
transmission fitness of Beijing strains with and without drug
resistance by analysing DNA fingerprint cluster data of a
population-based study in a rural area of Vietnam.
Methods
Study population and design
The study area consisted of three adjacent rural districts in Tien
Giang Province, situated in the Mekong River Delta in southern
Vietnam with a total population of 895,863, and a notification rate
of smear-positive TB of 100/100,000 (2003). Each has a district
TB unit (DTU) that performs sputum smear examinations and
treats ambulatory smear-positive patients according to the DOTS
strategy. Patients with severe smear-positive disease, as well as
suspects of smear-negative or extra-pulmonary TB, are referred
for diagnosis and treatment initiation to the provincial TB
hospital. There are no other laboratories that perform smear
examination, and private physicians do not treat TB. Population
movement is limited; the non-resident population was estimated at
around 1%. In 2001 the MDR-TB prevalence in the south of
Vietnam was 1.8% among new and 23% among previously
treated patients [23]. HIV testing of TB patients is done on clinical
suspicion only.
Diagnosis of smear-positive TB was by microscopic examination
of at least two Ziehl-Neelsen stained sputum smears [24]. Eligible
for inclusion were all patients aged 15 years or more who were
resident in the study area and registered for treatment of smear-
positive pulmonary TB at the participating DTU’s or at the
provincial TB hospital between 1 January 2003 and 31 December
2006. Patients in one of the districts were only eligible from 1
October 2003 onwards. Eligible patients were included upon
provision of written informed consent. Excluded were patients
who had been under treatment of the current TB episode for more
than two weeks before inclusion. Scientific and ethical clearance
was obtained from the Ethical Health Committee of the Ho Chi
Minh City Council.
Enrolled patients were interviewed using a standard question-
naire including items on socio-demographic information, details of
the patient’s households, clinical data, details of any previous TB
treatment, and history of possible infectious contact. Each patient
submitted two sputum specimens for mycobacterial culture that
were kept refrigerated and were transported to the Mycobacterial
Reference Laboratory in Ho Chi Minh City within 72 hours.
Laboratory methods
At the Reference Laboratory, sputum specimens were decon-
taminated and liquefied with 1% N-Acetyl-L-Cysteine (NALC) -
2% NaOH, inoculated on modified Ogawa medium and
incubated at 37uC [25]. Cultures with no growth after eight
weeks were reported as negative. M. tuberculosis was identified by
the niacin and nitrate tests. Drug susceptibility testing (DST) was
done by the proportion method following WHO/IUATLD
guidelines. Criteria for drug resistance were $1% colony growth
at 28 or 40 days compared to the drug-free control medium at the
following drug concentrations: isoniazid (H) 0.2 mg/ml, rifampin
(R) 40 mg/ml, streptomycin (S) 4 mg/ml and ethambutol (E) 2 mg/
ml [25]. DNA was extracted from M. tuberculosis cultures and
genotyped by spoligotyping [26], IS6110-based restriction frag-
ment length polymorphism (RFLP) typing [27] and 15-loci
variable numbers of tandem repeats (VNTR) typing [28,29].
IS6110 RFLP and spoligotype patterns were analyzed by using
Bionumerics software (Applied Maths, Sint-Martens-Latum,
Belgium) as described previously [30]. Similarity between the
DNA fingerprint patterns was calculated by using the Dice
coefficient with 1% position tolerance and optimization, and
UPGMA for clustering.
Definitions
The Beijing genotype was defined by spoligotyping as any
isolate without hybridization to spacers 1–34 and the presence of
$3 of the spacers 35–43 [6]. Other genotypes were defined as
described by Brudey et al [31], including the Vietnam genotype
that belongs to the East-African Indian (EAI) genotype family of
M. tuberculosis (designated EAI4-VNM) and is the most frequent
genotype in this study site [20].
A cluster was defined as $2 M. tuberculosis isolates sharing
identical or highly similar DNA fingerprints on basis of three
independent genetic markers [32]. We used criteria for clustering
based on the combination of results of IS6110 RFLP typing,
spoligotyping and VNTR typing. Only 100% identity was used for
clustering of IS6110 RFLP and spoligotype patterns. VNTR
patterns were considered similar if #1 VNTR locus displayed
more than one allele, and different when $2 loci displayed more
than one allele.
We defined M. tuberculosis infections as multiple .1 strain was
detected in a single patient isolate, based on discordant spoligo and
RFLP patterns and/or multiple VNTR loci with $1 allele [33].
Previous treatment was defined a history of anti-tuberculosis
treatment for $1 month [24]. A recurrent TB case was defined as
one that had been previously treated for TB with ‘treatment
completed’ or ‘default’ as the outcome. Re-infection was a case of
recurrent TB in which the isolated strain differed from that
Drug-Resistant M. tuberculosis Transmission
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isolated in the previous episode, while for relapse the strains was
the same, based on the definition for clustering mentioned above.
Data management and analysis
Data were entered in Epi-Info (version 6.04; Centers for Disease
Control and Prevention, Atlanta GA). Double entry was done on a
20% random sample (50% for 2003) of all records. Discrepancies
were observed in ,1% of all records, and in ,0.05% of all fields.
Analyses were performed in Stata (version 8; Stata Corp., College
Station TX). Patients with negative cultures or cultures that grew
non-tuberculous mycobacteria were excluded from the analyses, as
were patients with multiple infections or relapses.
In cases that presented with a double allele in one VNTR locus,
we based the cluster definition on one of these, and did a
secondary analysis in which we based the cluster definition on the
second allele at that locus. In the analyses, we compared the
proportions of patients who belonged to a cluster (i.e. shared a
fingerprint with $1 other patient in the database) to those of
patients who did not belong to a cluster (unique cases).
Of 210 strains belonging to spoligotype family EAI4 that were
initially typed by RFLP, 189 (86%) had ,5 IS6110 copies [31],
which limited the use of RFLP typing with regard to defining
transmission clusters within this group. Therefore we stopped
RFLP typing of the isolated strains except for those with a Beijing
spoligotype halfway the enrolment period. In the cluster analyses,
we made the assumption that all EAI strains for which no RFLP
data were available had ,5 IS6110 copies and thus belonged to
the same RFLP type, and that all strains with genotypes other than
EAI or Beijing (‘‘other’’) for which no RFLP data were available
had unique RFLP types. We verified this assumption by estimating
for each of the three major genotype groups (EAI, Beijing and
other) the numbers of strains not typed that were falsely classified
as being similar or different assuming that the isolates for which we
had RFLP data were a random selection of all isolates with regard
to the number (.5 or $5) of IS6110 copies.
For significance testing of comparisons of categorical variables,
the chi-square test or the two-sided Fisher’s exact test was used as
appropriate. Multivariate analyses were done by logistic regression
modeling. P-values for contribution to multivariate models,
including interaction, were based on the likelihood ratio chi-
squared test; p-values for contribution to models of individual
strata of variables were based on the Wald test; p-values for the
interaction of drug resistance on association between genotype
(Beijing vs. EAI) and MDR-TB were based on Mantel-Haenszel
stratification. All tests were done at the 5% significance level.
Results
Study population
Over the 4 year study period, 2573 smear-positive pulmonary
TB patients were registered for treatment, of whom 2531 met the
inclusion criteria. Twenty-one were excluded for technical errors,
90 for negative cultures and 47 for isolation of non-tuberculous
mycobacteria. After DNA typing of the remaining 2373 (92.2%)
isolates we excluded seven relapse cases and 159 mixed infections,
leaving 2207 patients for the analyses (87.2% of those enrolled;
Figure 1). Excluded patients were significantly older, more often
female and more often previously treated than included patients
(Table 1). RFLP information was lacking for 534 isolates including
four Beijing, 335 EAI, and 195 other genotype strains. The
estimated proportions falsely classified as similar were 0.3% for
Beijing strains and 3.0% for EAI strains, whereas the proportion of
other genotype strains falsely classified as different was 16.0%.
Clustering by genotype
Of the 2207 cases, EAI strains accounted for 36.3% (802
patients), Beijing strains for 35.6% (786) and other genotypes for
28.1% (619). The proportion Beijing strains increased slightly from
33.8% in the first year to 38% in the fourth year, whereas the
proportion EAI strains remained the same (33.8% to 33.1%) and
the proportion other strains decreased from 32.2% to 28.6%; these
differenced were not significant (p = 0.323). MDR was strongly
associated with the Beijing genotype: after multivariable adjust-
ment for year of inclusion, treatment history, residence, sex and
age the odds of MDR was 7.2 times higher among Beijing (68/786
cases, 8.7%) than among EAI or other genotypes (18/1421 cases,
1.3%; 95% CI 4.2–12.3, p,0.001).
We identified 936 patients (proportion; 95% CI) as being in one
of 245 clusters (42.4%; 40.4–44.5), with cluster sizes ranging from
two to 83 patients. Among patients infected with EAI genotypes,
527 were clustered (65.7%; 62.4–68.9) in 96 different clusters,
accounting for 39.2% of the total number of clusters. The
proportions in clusters were 292/786 (37.2%; 33.8–40.6) among
patients infected with Beijing strains and 117/619 (18.9%; 16.0–
22.1) among patients infected with other genotypes (Table 2). The
Beijing genotype accounted for 42.9% of the total number of
clusters (105/245) and predominantly occurred in cluster sizes of
two (69/140) while EAI predominantly occurred in cluster sizes of
three or more. Cluster of 10 or more cases were observed for EAI
strains (including one of 10, 16, 22 and 35 cases, respectively, and
two of 15 cases each), but not for Beijing and other genotype
strains.
Risk factors for clustering
In univariate analyses, compared to Beijing genotype infections,
clustering was more frequent with EAI genotype infections (odds
ratio (OR) 3.2; 95% CI 2.6–5.0) but less frequent with other
genotypes (0.4; 0.3–0.5). Clustering was also less frequent, albeit
non-significant, among streptomycin-resistant strains (0.9; 0.7–
1.0), ethambutol-resistant strains (0.8; 0.3–1.3) and MDR strains
(0.8; 0.5–1.2) (Table 3). Clustering was not associated with history
of TB treatment, year of inclusion, socio-demographic character-
istics (age, sex, residence, level of education, occupation, marital
status, family size) or the amount of time spent in places with
potential TB exposure such as markets, restaurants, offices,
hospitals, factories, schools, public transportation and prisons
(data not shown).
After multivariable adjustment for year of inclusion, treatment
history, drug resistance, residence, sex and age, the risk of
clustering remained significantly associated (adjusted OR (ORadj);
95% CI) with genotype (EAI vs. Beijing: 3.4; 2.8–4.4; other
genotypes vs. Beijing: 0.4; 0.3–0.5). Associations with drug
resistance disappeared or became non-significant. We found no
significant interactions between genotype and drug resistance
including MDR.
Effect of drug resistance on clustering by genotype
In order to compare the effects of drug resistance on the extent
of clustering within genotypes, we stratified the analysis by the two
predominant genotypes, i.e. EAI and Beijing, again taking the
proportion of clustered cases as the outcome, and adjusting the
associations for differences in year of inclusion, age, sex, residence
and previous TB treatment (Table 4). Among patients with Beijing
genotype infections, clustering was significantly more frequent if
the infecting strain was resistant than if the infecting strain was
susceptible to streptomycin (ORadj 1.3; 95% CI 1.0–1.8,
p = 0.041), to isoniazid (1.5; 1.1–2.1, p = 0.022) or to streptomycin
and isoniazid combined (1.5; 1.1–2.1, p = 0.023). Conversely,
Drug-Resistant M. tuberculosis Transmission
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among patients with EAI genotype infections clustering was less
frequent if the infection strain was resistant than if the infecting
strain was susceptible to streptomycin (0.6; 0.4–0.9, p = 0.016) or
to streptomycin-isoniazid (0.6; 0.4–1.1, p = 0.371, while there was
no difference in proportion clustering between EIA strains that
were resistant and EIA strains that were susceptible to isoniazid
only (0.9; 0.6–1.5, p= 0.912). The differences between Beijing and
EIA strains were statistically significant (p values for interaction
between resistance and genotype) for streptomycin resistance
(0.002) and for combined streptomycin-isoniazid resistance
(0.021). No clearly diverging patterns of the extent of clustering
between EAI and Beijing strains were observed for resistance to
rifampicin or ethambutol, or for MDR (Table 4).
Effect of streptomycin resistance on MDR
The apparently increased reproductive fitness of streptomycin-
resistant Beijing strains prompted us to further investigate the role
of streptomycin resistance in the association between MDR-TB
and genotype. We therefore stratified the adjusted relative risk of
MDR-TB among Beijing vs. non-Beijing genotypes by streptomy-
cin and combined streptomycin-isoniazid resistance status. Mul-
tivariate adjustment was again for age, sex, year of inclusion and
residence. We found that streptomycin resistance as well as
combined streptomycin-isoniazid resistance strongly confounded
the association between MDR-TB and genotype among both all
and new patients. While among all patients those with Beijing
strains had a 7.2-fold increased risk of MDR-TB compared to
non-Beijing strains, this risk was only 2.4 and 2.6 times increased
after adjustment for differences in streptomycin resistance and in
combined streptomycin-isoniazid resistance, respectively (Table 5).
Similarly, among new patients adjustment for resistance to
streptomycin and streptomycin-isoniazid resistance decreased the
relative risk of MDR-TB among Beijing infected patients from 8.8
to 2.9 and 3.0, respectively. In each comparison there was
significant interaction between streptomycin or streptomycin-
isoniazid resistance status and genotype. Further stratification
showed that the association between Beijing genotype and MDR-
TB completely depended on resistance to streptomycin: none of
the streptomycin-susceptible Beijing strains was MDR (Table 6).
Additional analyses
When we defined clusters by VNTR and spoligotyping only, the
proportion of patients in clusters increased to 80.4% (1774/2207).
This increase was substantial for Beijing and other genotypes from
37.2% to 98.6% and from 18.9% to 52.7%, respectively, but less
so for EAI genotypes (from 66.7% to 83.9%). Consequently, the
rate of clustering became lower for EAI than for Beijing genotype
strains, both before (OR 0.07) and after multivariable adjustment
as described above (ORadj 0.08; 95% CI 0.04–1.16, p,0.001).
Moreover, multidrug resistance appeared as a strong risk factor for
clustering (ORadj 6.2; 95% CI 1.1–34.8, p = 0.017). With this
limited cluster definition, the divergence between Beijing and EAI
genotypes with respect to the association between clustering and
streptomycin resistance became more pronounced: among pa-
tients infected with Beijing genotype strains streptomycin resis-
tance increased the proportion clustering by 2.9-fold (ORadj; 95%
CI 0.7–11.4), while among patients infected with EAI genotype
strains streptomycin resistance decreased the this proportion by
0.7-fold (0.4–1.2). This difference between the genotypes remained
significant (p = 0.050). Similarly, more pronounced differences in
proportions clustering between EAI and Beijing genotype strains
were observed for resistance to isoniazid and to ethambutol, as
well as for combined resistance to streptomycin and isoniazid;
these did however not reach statistical significance (data not
shown).
Discussion
In 42% of all patients the isolated strain had a DNA fingerprint
that clustered with that of at least one other patient. Beijing strains
Figure 1. Study flow chart of patient inclusion.
doi:10.1371/journal.pone.0042323.g001
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in general, i.e. not taking into account specific patterns of drug
resistance, displayed less clustering than EAI strains. This suggests
that Beijing strains are overall less transmissible than EAI strains.
However, because many of the EAI strains had few copies of
IS6110, the three-methods typing system we used may have had
reduced ability for discriminating EAI strains, resulting in an
overestimation of the extent of clustering for this genotype. That
such overestimation may have occurred was suggested by the
secondary analysis of fingerprint clusters based on VNTR and
spoligotyping only, which showed significantly more clustering for
Beijing than for EAI strains. One the other hand, this two-method
typing system may have overestimated the extent of clustering for
Beijing strains. Hence, our data cannot be considered conclusive
with regard to the overall transmission fitness of Beijing versus EAI
and other genotype trains.
Since the discriminatory power of the typing system is expected
to be similar within each genotype, we also looked at the
proportion clustering within the strata of the Beijing and EAI
genotypes separately. Strains that were resistant to streptomycin,
isoniazid or streptomycin and isoniazid combined showed higher
tendency for clustering than susceptible strains if they were of the
Beijing genotype, but not if they were EAI genotype. EIA strains
that were resistant to streptomycin were even significantly less
often clustered than EIA strains that were susceptible to
streptomycin. This suggests that while for EAI strains resistance
to streptomycin or streptomycin-isoniazid results in reduced
transmissibility, Beijing strains with these resistances have in fact
increased transmissibility, pointing to fitness differences between
resistant strains of these genotypes. The apparent key role for
streptomycin resistance is further supported by our finding that in
this setting the association between the Beijing genotype and
MDR-TB to large extent depended on the presence of strepto-
mycin resistance.
The overall proportion of clustering in our study was similar to
that found in Spain (42%) and Germany (49%), but lower than
clustering proportions in Russia (60%), Taiwan (67%) and South
Africa (72%) [9,34,35,36,37]. This may reflect differences in
transmission: our study was performed in a rural area while the
others were done in urban areas (Russia, South Africa) or in
hospitals (Taiwan, Spain) where transmission tends to be higher.
More likely, however, it reflects differences in typing methods.
Other studies used monotyping methods or combined two
methods, while we based our definition of fingerprint clusters on
a combination of three; IS6110 RFLP, spoligotyping and VNTR
typing. Our approach thereby maximized the likelihood that a
cluster represents epidemiologically related strains, but inherently
minimized the number of transmission clusters identified
[9,38,39]. Furthermore, when we used only spoligotyping and
VNTR typing results the proportion of clustered Beijing strains
increased, while this did not happen for EAI strains. Thus, VNTR
clusters of Beijing strains were split up by RFLP typing to
considerable extent, suggesting that VNTR typing has reduced
discriminatory power for Beijing strains and therefore analyses
based on VNTR and spoligotyping only falsely increase the
proportion clustering among Beijing strains. Comparing the results
of the two- versus the three-method typing system it thus seems
that our study is inconclusive with regard to the overall relative
reproductive fitness of Beijing versus EAI strains. On the other
hand, the pattern of differences between Beijing and EAI
genotypes in the extent of clustering of resistant versus susceptible
strains remained the same and even became more pronounced
when we defined clusters based on VNTR and spoligotyping only,
which indicates that this finding was robust to the typing system
used.
Our data suggest that streptomycin-resistant strains of the
Beijing genotype have no reduced, or even increased, reproductive
fitness. This finding is somewhat similar to that of studies from The
Netherlands and San Francisco that showed no reduced clustering
of isoniazid-resistant strains if they harbored the S315T mutation
in the katG gene, although in those studies no genotype association
was proven [40,41]. It prompted us to reassess our earlier finding
from this study site (on a then smaller dataset) of the strong
association between MDR and the Beijing genotype for an
underlying association with streptomycin-resistance [20], which
we indeed confirmed. We found that the association between
Beijing genotype and MDR became much weaker when it was
adjusted for differences in resistance to streptomycin with or
without resistance to isoniazid. This suggests that streptomycin
resistance is ‘‘on the causal pathway’’, i.e. that the association
between Beijing genotype and MDR is mediated by, or
conditional upon, resistance to streptomycin. In addition, when
we stratified this association by presence or absence of streptomy-
cin resistance it appeared to exist only among strains that were also
resistant to streptomycin. Taken together these findings strongly
suggest that in Vietnam streptomycin resistance is a prerequisite
for Beijing genotype strains to become MDR. A role of
streptomycin-resistance in the association between Beijing geno-
type and MDR has been suggested in several outbreaks of MDR-
TB, including in New York City and Kenya (in which 100% and
Table 1. Characteristics of the patients included or excluded
from the study among the 2573 enrolled patients.
Included patients
Excluded
patients p value
N
%
distribution N
%
distribution
Total 2207 366
Year of inclusion
2003 427 19.3 82 22.4 0.167
2004 638 28.9 103 28.1 0.764
2005 573 26.0 91 24.9 0.643
2006 569 25.8 90 24.6 0.629
District of residence
Cai Be 662 30.0 103 28.1 0.472
Cai Lay 910 41.2 152 41.5 0.902
Chau Thanh 635 28.8 111 30.3 0.555
Age (years)
,25 182 8.2 19 5.2 0.046
25–34 286 13.0 32 8.7 0.022
35–44 455 20.6 65 17.8 0.208
45–54 454 20.6 60 16.4 0.615
55–64 246 11.1 47 12.8 0.331
65+ 584 26.5 143 39.1 ,0.001
Sex
Male 1654 74.9 249 68.0 0.006
Female 553 25.1 117 32.0
History of TB treatment
New 1987 90.0 316 86.3 0.035
Previously treated 220 10.0 50 13.7
doi:10.1371/journal.pone.0042323.t001
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71%, respectively, of the MDR-TB Beijing/W strains were also
streptomycin-resistant) [42,43].
These findings raise the hypothesis that the association of
Beijing genotype with MDR is due to out-selection of streptomy-
cin-resistant Beijing strains that do not display reduced reproduc-
tive fitness in settings with high drug pressure for streptomycin.
This is the case in Vietnam, where streptomycin has been part of
the standard treatment regimen for new and/or previously treated
TB patients since 1986. It is likely also the case in many countries
of the Former Soviet Union, where streptomycin is part of the
standard first-line retreatment regimen and the proportion of TB
patients who have been previously treated is high [1]. As we
showed previously for Vietnam, co-existing isoniazid resistance
then strongly increases the risk of treatment failure [44], and
thereby for amplification to MDR. Whether this phenomenon
reflects a single, clonally expanded Beijing strain or several strains
requires further molecular studies, as do the specific mutations that
confer streptomycin-resistance in these strains. In our analyses
stratified by genotype we did not find any association between
extent of clustering and rifampin resistance or MDR. It may be
that Beijing strains that were streptomycin-resistant in addition to
MDR have higher transmission fitness than strains that are MDR
only, but numbers were too small to assess this.
Our study has a number of limitations in addition to those
mentioned. We assumed for the non-EAI, non-Beijing (‘‘other’’)
genotype strains for which we had no RFLP information that these
were all of different RFLP types, while 16% were estimated to
have similar RFLP patterns. This will have provided a minimum
estimate of clustering of these strains only, and is a probable
explanation why clustering among these strains was less than
among EAI or Beijing strains. We excluded strains with VNTR
types that had double alleles in $1 loci as mixed infections.
Table 2. Genotype and cluster distribution based on combined clustering of IS6110 RFLP, spoligotyping and VNTR typing, among
smear-positive pulmonary TB patients in rural Vietnam, 2003–2006.
Genotypes/sub-genotypes as defined by spoligotyping1 Isolated strains In cluster
n % n % (95% CI)
BEIJING 786 35.6% 292 37.2 (3.8–40.6)
Beijing 782 35.4% 290 37.1%
Beijing-like 4 0.20% 2 50.0%
EAI 802 36.3% 527 65.7 (62.4–68.9)
EAI4 VNM 389 17.6% 301 77.4%
EAI5 300 13.6% 203 67.7%
EAI2 MANILLA 71 3.2% 13 18.3%
EAI1 SOM 30 1.4% 10 20.0%
EAI2 NTB 11 0.5% 0 0.0%
EAI (undefined) 1 0.0% 0 0.0%
OTHERS 619 28.1% 117 18.9% (16.0–22.1)
NA 337 15.3% 34 10.1%
U 75 3.4% 11 14.7%
U(LIKELY H) 2 0.1% 0 0.0%
ZERO 67 3.0% 23 34.3%
T1 54 2.5% 26 48.2%
T2 17 0.8% 2 11.8%
T2T3 3 0.1% 0 0.0%
T3 4 0.2% 0 0.0%
T5 2 0.1% 0 0.0%
H3 38 1.7% 14 36.8%
H1 3 0.1% 0 0.0%
S 6 0.3% 5 83.3%
LAM9 2 0.1% 0 0.0%
MANU1 1 0.0% 0 0.0%
MANU2 1 0.0% 0 0.0%
CAS 2 0.1% 0 0.0%
CAS1DELHI 2 0.1% 0 0.0%
CAS1KILI 2 0.1% 0 0.0%
X2 1 0.0% 0 0.0%
TOTAL 2,207 100% 936 42.4% (40.4–44.5)
1Genotype or subgenotype classification was based on spoligotyping classification by Brudey et al. (SPOL4 database).
doi:10.1371/journal.pone.0042323.t002
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However, some of these minor allele differences could represent
evolution of the VNTR type within a single strain over time, and
we may thereby have wrongfully excluded them. In addition, we
did not collect data on HIV, although some studies suggested the
HIV is a risk factor for clustering of TB patients [45,46].
Nevertheless, since the estimated HIV prevalence among TB
patients in our site was less than 1% this is unlikely to have affected
our results [47].
Conclusions
While this study was inconclusive with respect to overall
differences in transmissibility between M. tuberculosis strains of the
Beijing genotype and strains of the East-African Indian lineage.
While we thus have no evidence that Beijing strains have a fitness
advantage over other genotype strains, our data do indicate that
Beijing strains retain their fitness if they are resistant to
streptomycin, whereas East African Indian strains do not.
Streptomycin-resistant Beijing strains even showed increased
Table 3. Univariable and multivariable associations of fingerprint clustering with socio-demography, history of tuberculosis
treatment and drug resistance among 2207 smear-positive pulmonary tuberculosis patients in Vietnam, 2003–2006.
Total
Patients in cluster
n (%) Crude OR p value
Adjusted
OR1 (95% CI) p value2
All patients 2207 936 (42.4%)
Genotype ,0.001 ,0.001
Beijing 786 292 (37.2%) 1 1
EAI 802 527 (66.7%) 3.2 3.4 (2.8–4.4)
Others 619 117 (18.9%) 0.4 0.4 (0.3–0.5)
Resistance to streptomycin 0.094 0.470
No 1617 703 (43.5%) 1 1
Yes 590 233 (39.5%) 0.9 1.1 (0.9–1.4)
Resistance to ethambutol 0.484 0.650
No 2169 922 (42.5%) 1 1
Yes 38 14 (36.8%) 0.8 1.2 (0.5–2.7)
Multidrug resistance 0.223 0.611
No 2121 905 (42.7%) 1 1
Yes 86 31 (36.0%) 0.8 0.9 (0.5–1.5)
TB treatment history 0.365 0.651
New 1987 849 (42.7%) 1 1
Previously treated 220 87 (39.5%) 0.9 1.1 (0.8–1.5)
Year of inclusion 0.143 0.071
2003 427 181 (42.4%) 1 1
2004 638 264 (41.4%) 1.0 0.9 (0.7–1.2)
2005 573 265 (46.2%) 1.2 1.1 (0.9–1.5)
2006 569 226 (39.7%) 0.8 0.8 (0.6–1.1)
Age (years) 0.088 0.105
,25 182 72 (39.6%) 1 1
25–34 286 116 (40.6%) 1.0 1.0 (0.6–1.5)
35–44 455 213 (46.8%) 1.3 1.2 (0.8–1.7)
45–54 454 207 (45.6%) 1.3 1.1 (0.7–1.5)
55–64 246 94 (38.2%) 0.9 0.8 (0.5–1.2)
65+ 584 234 (40.1%) 1.0 0.9 (0.6–1.2)
Sex 0.344 1.000
Male 1654 771 (46.6%) 1 1
Female 553 225 (40.7%) 0.8 1.0 (0.8–1.2)
Commune of residence 0.091 0.267
On waterway only 837 378 (45.2%) 1 1
On provincial road 1133 456 (40.2%) 0.8 0.9 (0.7–1.0)
On national road 237 102 (43.0%) 0.9 1.0 (0.7–1.4)
ORs: Odd ratios CI: confidence interval.
1Odd ratios adjusted by logistic regression for year of inclusion and all variables in the model.
2P values based on likelihood ratio test for excluding variable from logistic regression model.
doi:10.1371/journal.pone.0042323.t003
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reproductive fitness when compared to streptomycin-susceptible
Beijing strains. This suggests a selective advantage for these strains
in treatment programs that include streptomycin in their standard
regimens, which is further supported by out finding that
streptomycin resistance is a prerequisite for an increased risk of
MDR among Beijing strains in this setting. Tuberculosis control
programs in settings where similar associations exist should
reconsider the use of streptomycin.
Table 4. Association between fingerprint clustering and M. tuberculosis genotype (Beijing vs. East-African-Indian) by drug
resistance patterns among smear-positive pulmonary tuberculosis in rural Vietnam, 2003–2006.
Drug resistance East-African-Indian genotypes Beijing genotypes
p value for
interaction
2
Total In cluster n (%) Adjusted OR 1(95% CI) Total In cluster n (%)
Adjusted OR1
(95% CI)
Streptomycin
Susceptible 711 478 (67.2%) 1 398 134 (33.7%) 1 0.002
Resistant 91 49 (53.9%) 0.6 (0.4–0.9) 388 158 (40.7%) 1.3 (1.0–1.8)
Isoniazid
Susceptible 697 458 (65.7%) 1 555 192 (34.6%) 1 0.140
Resistant 105 69 (65.7%) 0.9 (0.6–1.5) 231 100 (43.3%) 1.5 (1.1–2.1)
Rifampicin
Susceptible 792 520 (66.7%) 1 706 260 (36.8%) 1 0.925
Resistant 10 7 (70.0%) 1.0 (0.3–4.2) 80 32 (40.0%) 1.2 (0.7–1.9)
Ethambutol
Susceptible 799 525 (65.7%) 1 760 281 (37.0%) 1 0.822
Resistant 3 2 (66.7%) 1.0 (0.1–12.0) 26 11 (42.3%) 1.3 (0.6–2.9)
Streptomycin and isoniazid
Susceptible 750 479 (66.3%) 1 575 200 (34.8%) 1 0.021
Resistant 52 30 (57.7%) 0.6 (0.4–1.1) 211 92 (43.6%) 1.5 (1.1–2.1)
Rifampicin and isoniazid
Susceptible 795 522 (65.7%) 1 718 267 (37.2%) 1 0.875
Resistant 7 5 (71.4%) 1.2 (0.2–6.5) 68 25 (36.8%) 1.0 (0.6–1.7)
ORs: Odds ratios, with 95% confident interval CI: Confidence interval.
1Adjusted by logistic regression modeling for year of inclusion, age, sex, commune of residence and history of tuberculosis treatment.
2P values based on Wald test for comparison of stratum to reference category. Denotes the level of significance for the difference between East-African-Indian and
Beijing genotypes in the association of clustering and drug resistance.
Table 5. The role of streptomycin resistance and combined streptomycin-isoniazid resistance on the association between M.
tuberculosis genotype (Beijing vs. non-Beijing) and multi-drug resistance among smear-positive pulmonary TB patients in rural
Vietnam, 2003–2006.
Total
MDR-TB
n (%)
OR
(95% CI)1
OR adjusted for
resistance to
streptomycin
(95% CI)2
OR adjusted for
combined resistance to
streptomycin and
isoniazid
(95% CI)3
All smear positive pulmonary TB
Non Beijing 1421 18 (1.3%) 1 1 1
Beijing 786 68 (8.7%) 7.2 (4.2–12.3) 2.4 (1.4–4.2) 2.6 (1.4–4.6)
New smear positive pulmonary TB
Non Beijing 1324 10 (0.8%) 1 1 1
Beijing 663 42 (6.3%) 8.8 (4.4–17.9) 2.9 (1.4–6.1) 3.0 (1.4–6.5)
ORs: Odds ratios, CI: Confidence interval.
MDR-TB: multi-drug resistance tuberculose.
1Adjusted for age, sex, year of inclusion, commune of residence by logistic multivariate regression model.
2Adjusted for Age, sex, year of inclusion, commune of residence and streptomycin resistance by logistic multivariate regression model.
3Adjusted for Age, sex, year of inclusion, commune of residence and combined resistance to streptomycin and isoniazid by logistic multivariate regression model.
doi:10.1371/journal.pone.0042323.t005
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